[go: up one dir, main page]

WO2004015422A3 - Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1) - Google Patents

Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1) Download PDF

Info

Publication number
WO2004015422A3
WO2004015422A3 PCT/EP2003/008048 EP0308048W WO2004015422A3 WO 2004015422 A3 WO2004015422 A3 WO 2004015422A3 EP 0308048 W EP0308048 W EP 0308048W WO 2004015422 A3 WO2004015422 A3 WO 2004015422A3
Authority
WO
WIPO (PCT)
Prior art keywords
ogr
therapeutics
diagnostics
ovarian cancer
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008048
Other languages
French (fr)
Other versions
WO2004015422A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to AU2003266238A priority Critical patent/AU2003266238A1/en
Publication of WO2004015422A2 publication Critical patent/WO2004015422A2/en
Publication of WO2004015422A3 publication Critical patent/WO2004015422A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human OGR-1 which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, inflammation, hematological disease and gastro-intestinal diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, inflammation, hematological disease and gastro-intestinal diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of OGR-1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/008048 2002-08-05 2003-07-23 Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1) Ceased WO2004015422A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003266238A AU2003266238A1 (en) 2002-08-05 2003-07-23 Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016980.1 2002-08-05
EP02016980 2002-08-05

Publications (2)

Publication Number Publication Date
WO2004015422A2 WO2004015422A2 (en) 2004-02-19
WO2004015422A3 true WO2004015422A3 (en) 2004-03-18

Family

ID=31502684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008048 Ceased WO2004015422A2 (en) 2002-08-05 2003-07-23 Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)

Country Status (2)

Country Link
AU (1) AU2003266238A1 (en)
WO (1) WO2004015422A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5292712B2 (en) * 2007-03-23 2013-09-18 日本電気株式会社 Authentication linkage system, relay device, authentication linkage method, and authentication linkage program

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834565A2 (en) * 1996-10-03 1998-04-08 Smithkline Beecham Corporation A G-protein coupled receptor HUVCT36
WO2000006597A2 (en) * 1998-07-31 2000-02-10 Arena Pharmaceuticals, Inc. Endogenous constitutively activated g protein-coupled orphan receptors
WO2002020556A2 (en) * 2000-09-07 2002-03-14 Genaissance Pharmaceuticals, Inc. Haplotypes of the gpr68 gene
WO2002024222A2 (en) * 2000-09-20 2002-03-28 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002079438A2 (en) * 2001-03-29 2002-10-10 Deltagen, Inc. Ogri gene disruptions, compositions and methods relating thereto
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
WO2003039341A2 (en) * 2001-11-05 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834565A2 (en) * 1996-10-03 1998-04-08 Smithkline Beecham Corporation A G-protein coupled receptor HUVCT36
WO2000006597A2 (en) * 1998-07-31 2000-02-10 Arena Pharmaceuticals, Inc. Endogenous constitutively activated g protein-coupled orphan receptors
WO2002020556A2 (en) * 2000-09-07 2002-03-14 Genaissance Pharmaceuticals, Inc. Haplotypes of the gpr68 gene
WO2002024222A2 (en) * 2000-09-20 2002-03-28 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002079438A2 (en) * 2001-03-29 2002-10-10 Deltagen, Inc. Ogri gene disruptions, compositions and methods relating thereto
WO2003014731A2 (en) * 2001-08-07 2003-02-20 Euroscreen S.A. The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
WO2003039341A2 (en) * 2001-11-05 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWISS-PROT [online] XP002267249, Database accession no. Q15743 *
HOFFERT C ET AL: "Distribution of ovarian cancer G-protein coupled receptor 1 in human and rat nervous tissue", BIOSIS, XP002209174 *
XU Y ET AL: "SPHINGOSYLPHOSPHORYLCHOLINE IS A LIGAND FOR OVARIAN CANCER G-PROTEIN-COUPLED RECEPTOR 1", NATURE CELL BIOLOGY, MACMILLAN PUBLISHERS, GB, vol. 2, no. 5, May 2000 (2000-05-01), pages 261 - 267, XP008013921, ISSN: 1465-7392 *

Also Published As

Publication number Publication date
WO2004015422A2 (en) 2004-02-19
AU2003266238A8 (en) 2004-02-25
AU2003266238A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2003074069A3 (en) Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2004015422A3 (en) Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2003065044A8 (en) Diagnostics and therapeutics for diseases associated with gpr72
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
WO2004015427A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2004038416A8 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2003076945A3 (en) Diagnostic for diseases associated with g-protein coupled receptor 105 (gpr105)
WO2004038408A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004048978A3 (en) Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP